Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMETHYST: AL0704rP in Timothy Grass Pollen Allergic Rhinoconjunctivitis
NCT00671268Phase 3Completed
- Sponsor
- Allergopharma
- Start
- Mar 2008
- Primary completion
- Mar 2012
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in allergic rhinoconjunctivitis (ARC) comparing AL0704rP with Placebo (2 arms). Primary endpoint: Symptom and Medication Score at 2 years. Started Mar 2008; status: completed.
02
Drugs
recombinant timothy grass pollen allergen cocktail
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on NCT00671268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00671268.